Cardiomyopathy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are 18 years of age or older
- People with breast cancer who are starting treatment with doxorubicin or another similar chemotherapy drug (called an anthracycline), or who are receiving a drug called trastuzumab without that type of chemotherapy, as part of treatment before or after surgery
- People who are able to understand what the trial involves, including its requirements, risks, and possible discomforts
- People who are willing and able to sign a consent form agreeing to take part
- People who fall into one of these three groups: (1) those who have been diagnosed with heart-related problems that may be linked to previous cancer treatment — such as heart muscle damage, heart failure, reduced heart pumping ability, heart attack, blocked arteries in the limbs, irregular heartbeat, or heart inflammation; OR (2) those who have finished chemotherapy with no heart problems and it has been at least two years since treatment ended; OR (3) those with cancer who are about to start a treatment that could affect the heart, such as doxorubicin or trastuzumab
- People who are generally healthy, not pregnant, and weigh at least 110 pounds (approximately 50 kg)
Who may not be able to join:
- People who are unable to understand the consent form or are unlikely to be able to follow the trial's requirements
- People who have low red blood cell levels (a hemoglobin level below 8) (confirm with trial site for exact measurement units)
- People who are not willing to have a blood sample taken
- People who have stage IV breast cancer, meaning the cancer has spread to distant parts of the body
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Nadine Norton, Ph.D., Mayo Clinic
Phone: 855-776-0015
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Significance ofTRPC6 coding sequencing
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.